In this week's Expert View piece, Laurie Halloran, founder and chief executive of the Halloran Consulting Group, considers the changing role of contract research organizations in the discovery and development of new pharmaceuticals.
A decade ago, experts were predicting further integration of contract research organizations (CROs) in clinical trials.
And for the most part, they were right. What used to be a vertical, top-down, fixed reporting model industry swiftly shifted to a mixed model utilizing both internal and external resources to conduct clinical trials. But as companies steadily increased their dependence on outside resources, cracks in the system started to show. In recent years, companies have examined the amount of effort and resources it takes to oversee these external resources, as well as the quality of work and the cost associated with them, and the results were not pretty. This has led some of the most “innovative” companies to rethink their outsourcing models altogether. They are bringing certain functions back inhouse to reduce the amount of work out-sourced throughout all phases of clinical trials, from conception to completion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze